Clinical trial
Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years
NCT01001169 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine (GSK2340274A) in Japanese Children Aged 6 Months to 17 Years
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 1, 2009
- Completion date
- May 17, 2010
- Enrollment
- 60 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
influenza